Jazz Pharmaceuticals (JAZZ) Form 144: 3,731 Shares from Restricted Vesting

Rhea-AI Filing Summary

Rule 144 notice: The filer proposes to sell 3,731 shares of common stock of Jazz Pharmaceuticals (JAZZ) with an aggregate market value of $417,872.00. The proposed trades are to occur on NASDAQ with an approximate sale date of 08/08/2025. The securities were acquired the prior day, 08/07/2025, through restricted stock vesting from the issuer and the stated nature of payment is compensation.

The notice reports nothing to report for securities sold during the past three months. The filer affirms, by signing the form, they do not possess undisclosed material adverse information about the issuer. This filing is a routine Rule 144 disclosure describing an intended sale of newly vested shares under standard resale procedures.

Insights

Securities Analyst

TL;DR Routine insider resale of newly vested shares; limited immediate market impact given disclosed size.

The filing notifies the market of an intended sale of 3,731 common shares valued at $417,872.00 to be executed on NASDAQ. The shares were acquired by restricted stock vesting and are being sold under Rule 144 resale procedures. The filing states no other sales in the past three months, which reduces concerns about ongoing disposal. This is a standard disclosure that provides transparency on potential insider supply entering the market but contains no information on material corporate events.

Corporate Governance Expert

TL;DR Compliance-focused notice showing standard handling of vested equity and insider attestation.

The document documents compliance with Rule 144 for the proposed sale and includes the required attestation that the seller lacks undisclosed material adverse information. The acquisition method is listed as restricted stock vesting with payment characterized as compensation, indicating the shares originated from employee equity compensation. No past three-month sales are reported, and the filing contains the routine legal warning about misstatements. Governance implications are procedural rather than substantive.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
COMMON	ETRADE FINANCIAL CORPORATION ETRADE FINANCIAL CORPORATION 3 EDISON DRIVE ALPHARETTA GA 30005	3731	417872.00	60658809	08/08/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
COMMON	08/07/2025	RESTRICTED STOCK VESTING	ISSUER			3731	08/07/2025	COMPENSATION

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What shares does the JAZZ Form 144 report propose to sell?

The notice proposes sale of 3,731 shares of Jazz Pharmaceuticals common stock.

What is the aggregate market value of the shares in the JAZZ Form 144?

The aggregate market value reported is $417,872.00.

When were the shares acquired according to the Form 144 for JAZZ?

The shares were acquired on 08/07/2025 by restricted stock vesting from the issuer.

When is the approximate date of sale listed in the JAZZ Form 144?

The approximate date of sale is listed as 08/08/2025 on NASDAQ.

Has the filer sold any JAZZ securities in the past three months?

The filing reports Nothing to Report for securities sold during the past three months.